Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for COH.AX and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for COH.AX and 80,000+ other tickers.
See exactly how COH.AX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for COH.AX and 80,000+ other tickers.
Globally, Cochlear Limited specializes in the development and provision of implantable auditory solutions for both children and adults. The company's diverse offerings include advanced cochlear implant systems, upgrades for sound processors, bone conduction devices, and a wide array of accessories and other related items. Established in 1981, its global operations are directed from its headquarters in Sydney, Australia.
Don't Miss the Moments That Matter This Summer: Hearing Experts and Cochlear Encourage People to Check Their Hearing Health PR
Better Hearing and Whole-Body Health: What to Know About MRI Access with Cochlear Implants PR Newswire LONE TREE